(Q34936164)

5 August 2017

1 reference

title

Treatment of recurrent hepatitis C. (English)

1 reference

5 August 2017

1 reference

Ed Gane

1

1 reference

5 August 2017

publication date

1 October 2002

1 reference

5 August 2017

published in

Liver Transplantation

1 reference

5 August 2017

volume

8

1 reference

5 August 2017

issue

10 Suppl 1

1 reference

5 August 2017

page(s)

S28-37

1 reference

Long-term outcome of hepatitis C infection after liver transplantation

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

The association between hepatitis C infection and survival after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Analysis of causes of death in liver transplant recipients who survived more than 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

A longitudinal analysis of hepatitis C virus replication following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Recurrent and new hepatitis C virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Hepatitis C virus kinetics during and immediately after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Interferon-alpha therapy for hepatitis C virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Daily interferon therapy for hepatitis C virus infection in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Immunological and virological effects of ribavirin in hepatitis C after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Ribavirin therapy for hepatitis C infection following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Ribavirin inhibits protein synthesis and cell proliferation induced by mitogenic factors in primary human and rat hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Combination of interferon induction therapy and ribavirin in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Hepatitis C, interferon alfa, and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Quality of life, functional status, and depression in male liver transplant recipients with recurrent viral hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

The impact of liver disease and medical complications on quality of life and psychological distress before and after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Evidence for a cerebral effect of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Paroxetine for the prevention of depression induced by high-dose interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Interferon-alpha-induced acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Predictors of patient and graft survival following liver transplantation for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Treatment of acute hepatitis C with interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Effect of immune globulin on the prevention of experimental hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Mycophenolate mofetil strongly potentiates the anti-herpesvirus activity of acyclovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Indication for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

Interferon-alpha plus ribavirin and amantadine in patients with post-transplant hepatitis C: results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.35860

21 January 2018

Identifiers

DOI

10.1053/JLTS.2002.35860

1 reference

5 August 2017

1 reference